



27 January 2016

ASX ANNOUNCEMENT

FDA Approves New Range of Respiratory Devices

Medical Developments International Limited (ASX: MVP) is delighted to announce that it has received approval from the US Food and Drug Administration (FDA) to sell its new range of anti-static respiratory devices in the USA.

The approval represents a significant opportunity to build MDI's global respiratory business, particularly in the USA. This approval was anticipated and recent marketing efforts means the approval complements a number of Distribution Agreements entered into with North American business partners over the last month. As a consequence, MVP expects to achieve new sales in the near term.

MVP CEO Mr. John Sharman said: "The recent approval of our North American range of anti-static respiratory devices represents a significant sales opportunity for us in North America and complements our range of global opportunities including the recent acquisition of Breath-A-Tech in Australia."

Mr. Sharman said, "Our global Respiratory Device business is showing great promise. We have received our first sales order from one of our new North American distributors which we expect to deliver in the next month. We expect to deliver good sales growth from our respiratory business in the months and years ahead."

Enquiries:

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

David Williams
Chairman
Medical Developments International Ltd
0414 383 593



About Pentrox

Pentrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Pentrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Pentrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.